Best peptides for weight loss
FDA-approved and research-stage peptides targeting weight management and metabolic health.
The GLP-1 revolution has put peptides at the center of weight management. But not all weight-loss peptides are equal — some are FDA-approved with massive clinical trials, while others have minimal evidence. Here is an honest ranking based on research strength.
Prescription-only weight management peptides including Ozempic, Wegovy, and Mounjaro. The most clinically proven class of peptides for obesity and type 2 diabetes management. Oral versions now exist too — oral semaglutide (Rybelsus) is FDA-approved, and orforglipron, the first oral small-molecule GLP-1 drug, was approved in April 2026. PRESCRIPTION ONLY.
What evidence supports
- ✓large-scale clinical trials demonstrate 15–20% body weight reduction
- ✓FDA-approved for obesity (BMI 30+) and type 2 diabetes management
- ✓cardiovascular outcome benefits documented in major trials
Key concern: prescription only — not available or appropriate without physician oversight
Available in
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Often compared to semaglutide, tirzepatide has shown slightly greater weight loss in head-to-head trials due to its dual-action mechanism.
What evidence supports
- ✓FDA-approved for type 2 diabetes and chronic weight management
- ✓SURMOUNT trials showed up to 22.5% body weight reduction at highest dose
- ✓head-to-head SURPASS-2 trial showed superior A1C reduction vs semaglutide 1mg, and the later SURMOUNT-5 head-to-head trial (2025) showed greater weight loss than semaglutide as well (20.2% vs 13.7% at 72 weeks)
Key concern: GI side effects (nausea, vomiting, diarrhea) affect 15-25% of users, especially during dose escalation
The first once-daily injectable GLP-1 receptor agonist to achieve widespread clinical use, approved for type 2 diabetes (Victoza, 2010) and obesity (Saxenda, 2014). Historically the reference GLP-1 therapy, now largely superseded by once-weekly semaglutide in practice — but still widely prescribed with a 15+ year safety record.
What evidence supports
- ✓SCALE Obesity trial (3731 participants): Saxenda 3mg achieved 8.4% mean weight loss vs 2.8% placebo at 56 weeks
- ✓LEADER trial: liraglutide reduced MACE by 13% in T2D with established CV disease (HR 0.87)
- ✓Victoza reduces HbA1c by ~1–1.5% in T2D patients
Key concern: GI side effects (nausea, vomiting, diarrhea) affect the majority of users early in treatment
An orally active growth hormone secretagogue that mimics ghrelin, the hunger hormone. Despite being widely sold alongside peptides and SARMs, MK-677 is technically a non-peptide small molecule. It was studied extensively but never FDA-approved, and carries significant metabolic concerns.
What evidence supports
- ✓consistently raises GH and IGF-1 levels in clinical studies
- ✓oral bioavailability is a significant practical advantage over injectable peptides
- ✓two-year study showed sustained IGF-1 elevation without tachyphylaxis
Key concern: significantly increases appetite — can lead to unwanted weight gain
A long-acting amylin analog being developed by Novo Nordisk. Most significant as the amylin component of CagriSema — a fixed-dose weekly injection combining cagrilintide 2.4mg with semaglutide 2.4mg. Phase 3 REDEFINE trials published in the New England Journal of Medicine (June 2025) showed mean weight loss of over 20%, among the highest ever recorded for a pharmacological intervention. FDA review expected in 2026.
What evidence supports
- ✓REDEFINE 1 (NEJM, June 2025, n=3,417): CagriSema produced mean body weight reduction of 20.4% vs 3.0% placebo at week 68 — 60% of participants achieved ≥20% weight loss, 23% achieved ≥30%
- ✓REDEFINE 2 (NEJM, June 2025, n=1,206 with type 2 diabetes): 13.7% weight reduction vs 3.4% placebo; 73.5% reached HbA1c ≤6.5% vs 15.9% with placebo
- ✓significantly improved systolic blood pressure, waist circumference, and lipid levels in both trials
Key concern: CagriSema is not yet FDA or EMA approved — currently accessible only through clinical trials or off-label compounding
A triple hormone receptor agonist (GLP-1/GIP/glucagon) developed by Eli Lilly, representing the next generation of obesity treatments beyond semaglutide and tirzepatide. Phase III trials (TRIUMPH-1) have now shown weight loss of up to 28.3% of body weight at 80 weeks, up from the 24.2% seen in earlier Phase II data.
What evidence supports
- ✓Phase III TRIUMPH-1 trial (obesity, ~2,339 adults) showed 28.3% average weight loss at 80 weeks at the top dose, with close to half of participants losing 30% or more — surpassing the earlier Phase II ceiling
- ✓TRIUMPH-4 (obesity plus knee osteoarthritis) showed a similar 28.7% loss at 68 weeks
- ✓TRANSCEND-T2D-1 showed 16.8% weight loss in people with type 2 diabetes at 40 weeks
Key concern: still in clinical development — not yet FDA approved
A mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. MOTS-c has gained significant attention in longevity and metabolic health communities for its exercise-mimicking effects and role in cellular energy regulation. Research is promising but still early-stage.
What evidence supports
- ✓activates AMPK signaling pathway in cell and animal studies
- ✓improved glucose metabolism and insulin sensitivity in mouse models
- ✓exercise-induced increase in circulating MOTS-c levels documented in humans
Key concern: no completed human clinical trials for therapeutic use — though a Phase 2a trial in prediabetes and insulin resistance is now underway (recruiting/running as of 2026), so this is starting to change
A small molecule NNMT inhibitor that has gained popularity in biohacking and weight-loss communities for its potential to boost cellular energy expenditure and reduce fat accumulation. Technically not a peptide, but widely discussed and sold alongside peptides in the metabolic health space.
What evidence supports
- ✓NNMT inhibition reduced body weight and fat mass in diet-induced obese mice
- ✓cell studies show NNMT inhibition increases NAD+ levels and energy expenditure in adipocytes
- ✓NNMT is overexpressed in adipose tissue of obese individuals (validated target)
Key concern: no published human clinical trials — all evidence is preclinical
Available in
Not sure which is right for you?
Take our quiz for a personalized recommendation based on your goals and preferences.
Take the Peptide QuizMedical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.